In over 90 clinical scenarios of patients commonly seen by physicians with possible coronary artery disease, nuclear imaging, echo, CTA, exercise stress testing, MR, and angiography were compared against each other for the most appropriate approach for patient care.
Dr. Matthew Simon and colleagues have published a research study on the cost-effectiveness of novel screening strategies for preventing transfusion-transmitted babesiosis, the most common red blood cell transfusion-transmitted infection in the United States. The results suggest that, in highly endemic states such as New York, screening donated blood for antibodies to Babesia, would avoid additional cases and would be cost-effective relative to currently implemented blood supply screening for...
Dr. Richard Furman, Division of Hematology & Medical Oncology, and co-authors have published a landmark paper in the New England Journal of Medicine. Their results utilizing the drug, Idelalisib, in a randomized, double-blinded study (5 countries) suggest that a common form of leukemia may be treated without toxic chemotherapy.
Department of Medicine physicians have published a pivotal paper on patient care transitions in Academic Medicine. The study evaluated findings from a resident-staffed early post-discharge program. A goal of any academic medical center is to ensure a patient's safety after discharge from the hospital. This often includes visits and follow-up care at outpatient practices that are staffed by residents-in-training. However, residents may not always be comfortable managing patient care transition.
Building on the Melnick Lab's research identifying novel disease mechanisms and therapeutic targets in B-cell lymphomas, the 4th most common malignancy in the United States. Dr. Béguelin will present her recent discoveries outlining the mechanism of action of a protein called EZH2, which functions as a histone methyltransferase that silences gene expression.
Dr. Vivian Bykerk, on staff at the Hospital for Special Surgery (HSS) and an Associate Professor of Medicine (Department of Medicine) at Weill Cornell, presented advances in arthritis research at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professions. The message of the new findings was: Delaying treatment for rheumatoid arthritis can greatly increase the likelihood of worse function at two years.
On the heels of numerous advancements by the Melnick Lab, the latest breakthrough involves an experimental new drug that is capable of completely eradicating human lymphoma in mice after five doses. Published in Cell Reports (August 2013), this finding sets the stage for clinical trials that would use an experimental drug for the treatment of B-cell lymphoma (DLBCL).
Dr. Gail Roboz, Associate Professor of Medicine and Director of the Leukemia Program at NYP/WC, has been named lead investigator for a Sunesis Pharmaceuticals-funded clinical trial for the treatment of myelodysplastic syndrome (MDS). A Phase I/II (open-label, dose escalating) trial, it is set to enroll approximately 40 patients with MDS who previously experienced failed treatment using hypomethylating agent-based therapy.
Chemoresistant diffuse large B-cell lymphoma (DLBCL) is a devastating illness that affects thousands of people each year in the United Stats, but there is good news to report. Dr. Leandro Cerchietti and Dr. Peter Martin, both members of the Division of Hematology and Medical Oncology, published a paper in Cancer Discovery in September 2013 that sheds light on the mechanisms by which DLBCL becomes resistant to chemotherapy and how those changes might be reversed.
On the heels of a series of advancements by the Suthanthiran Lab, the team has published a landmark paper in the New England Journal of Medicine (NEJM) showing that a urine biomarker test which they have devised in the lab, can not only diagnose, but predict, rejection of transplanted kidneys.
